Financial Performance - The Company has a history of net losses and Adjusted EBITDA losses, indicating challenges in achieving growth objectives[45]. - Financial performance in 2023 fell short of expectations, with a 5-year average revenue of $12,175,532 per year, impacted by macroeconomic factors such as high interest rates and supply chain issues[70]. - The company reported a working capital of $5,026,580 as of December 31, 2023, indicating a strong liquidity position for ongoing operations and R&D initiatives[79]. - The company reported net earnings of $447,397 for the year ended December 31, 2025, a significant recovery from a net loss of $4,622,297 in 2024[111]. - For the year ended December 31, 2025, the Company reported revenues of $10,784,090, a slight increase from $10,680,468 in 2024, indicating stability in the business model[140]. - The gross profit for 2025 was $4,432,744, representing a gross profit margin of 41%, down from 44% in 2024[149]. - Total expenses for 2025 were $3,989,053, significantly reduced from $5,527,559 in 2024, primarily due to decreased consulting and administrative costs[150]. - The Company achieved a gross profit margin of 44% on revenues of $10,680,468 for the year ended December 31, 2024, up from 42% on revenues of $10,819,916 in 2023[158]. Operational Challenges - The Company may not have sufficient capital to meet increases in business demands, potentially affecting its ability to grow operations[44]. - The Company’s production facilities may not be large enough to handle growth in market demand, impacting revenue generation[53]. - The Company may face shortages of parts and raw materials, which could hinder business development plans and revenue[52]. - The Company is subject to risks from customer order cancellations, which could negatively impact revenue if component parts have already been ordered[49]. - The Company may encounter unforeseen competition that could affect its ability to maintain projected revenue levels[48]. - The Company may face risks related to international conflicts and geopolitical tensions, which could disrupt supply chains and impact financial performance[41]. Research and Development - The Company invests in R&D activities focused on innovation, but returns on these investments are uncertain and may not yield immediate financial performance[39]. - The Company has made considerable progress in R&D for new products, although the timing of regulatory approvals remains unpredictable[77]. - The Company has impaired its capitalized research and development (R&D) to a nominal $1, reflecting challenges in securing funding for the KXI project[90]. - The Company is actively exploring strategic alternatives for the KXI project, including potential joint ventures and licensing agreements[90]. - The Company plans to continue developing new rail products to create financial growth opportunities despite current market challenges[143]. Product Development and Market Strategy - The K2AV product is on track to complete its field service trial by 2025, with AAR approval expected to significantly increase revenue potential from pressure cars, raising average sales from $1,500 to over $10,000 per car[82]. - The Company aims to leverage its competitive advantages in the rail industry despite challenges, with a focus on diversifying its product portfolio and obtaining AAR approvals for new products[81]. - The Company plans to strengthen its tank car product portfolio with ongoing field service trials for new valves, which are expected to generate higher unit sales and increase revenue[84]. - The tank car market is shifting towards repurposing and re-qualifying existing fleets, presenting revenue growth opportunities for the Company in repair and retrofit services[86]. - The Company has capitalized on the need for safer valve solutions, generating over $147 million in revenues since 2012 from distributing over 100,000 valves[120]. Financial Management and Capital Resources - The Company has increased its line of credit with Texas Capital Bank from $500,000 to $1 million, indicating improvements in fiscal management[99]. - The Company anticipates that its capital resources will enable it to continue operations as planned for the foreseeable future[171]. - The Company’s working capital increased to $2,541,625 in 2025 from $2,125,387 in 2024, reflecting improved liquidity[140]. - The Company had cash on deposit of $399,375 and inventory of $2,206,770 as of December 31, 2025, compared to cash of $153,147 and inventory of $3,042,749 as of December 31, 2024[170]. Executive Compensation and Governance - Frank Busch serves as the Director, President, and CEO, with a total compensation of $300,000 for Fiscal Year 2025[189]. - Sameer Uplenchwar, the Chief Financial Officer, has a total compensation of $240,000 for Fiscal Year 2025[189]. - Amanda Smith, the Chief Operating Officer, received a total compensation of $222,879 for Fiscal Year 2025[189]. - The Company has entered into Professional Services Agreements with its executives, ensuring structured compensation and performance incentives[190][192]. - The Company has a severance clause for executives equal to 6 months of base salary in the event of termination without cause[190]. - The Compensation Committee is responsible for overseeing compensation policies approved by the Board[226]. Audit and Compliance - The Audit Committee is responsible for reviewing both interim and annual financial statements, with members having the right to inspect all books and financial records of the Company[224]. - The former auditors, Smythe LLP, resigned on September 25, 2025, and were replaced by CBIZ CPAs P.C. effective October 6, 2025[225]. - The Committee reviews the financial reporting process to ensure the accuracy of the Company's financial statements[226]. - It evaluates the independent auditor's qualifications, performance, and independence[226]. - The Committee monitors compliance with laws and regulations[226].

Financial Performance - Net sales for 2025 were $10,142, an increase of $769, or 8.2%, from $9,373 in 2024, driven by higher sales of wired sensing products and HazardPRO™ wireless systems[73] - Gross profit for 2025 increased $575, or 12.5%, to $5,157 from $4,582 in 2024, with a gross margin of 50.8% compared to 48.9% in 2024[75] - Total operating expenses increased $569, or 12.4%, to $5,155 in 2025 from $4,586 in 2024, rising as a percentage of net sales to 50.8% from 48.9%[76] - Operating income was $2 in 2025 compared to an operating loss of $4 in 2024, marking an increase of $6, or 150.0%[78] - Net income decreased by $140, or 31.4%, to $306 in 2025 from $446 in 2024, with basic and diluted earnings per share at $0.09 and $0.13, respectively[82] Cash and Liquidity - Cash and cash equivalents were $10,545 at December 31, 2025, compared to $9,948 at December 31, 2024, with working capital increasing to $13,468 from $12,922[84] - Cash generated from operating activities was $662 in 2025, an increase of $533 from $129 in 2024[85] - Cash equivalents as of December 31, 2025, were $7,985,000, compared to $7,980,000 in 2024, showing a slight increase[125] Assets and Equity - Total assets increased to $15,702,000 in 2025 from $14,885,000 in 2024, representing a growth of 5.5%[111] - Total stockholders' equity grew to $14,817,000 in 2025, up from $14,333,000 in 2024, an increase of 3.4%[111] - Trade receivables, net of allowance for credit losses, increased to $1,404,000 in 2025 from $1,309,000 in 2024, a rise of 7.3%[111] Expenses and Investments - Total operating expenses totaled $5,155,000 in 2025, compared to $4,586,000 in 2024, an increase of 12.4%[113] - Research and development expenses were $991,000 in 2025, down from $1,013,000 in 2024[145] - The Company believes its ongoing cash usage requirements will be primarily for capital expenditures, potential acquisitions, and research and development[87] Taxation - Total Federal and State Income Taxes for 2025 amounted to $41,000, compared to a tax provision of $(10,000) in 2024, reflecting a significant increase[10]. - The computed "Expected" Federal Tax Expense for 2025 was $73,000, representing 21.0% of pretax income, slightly down from $92,000 or 21.1% in 2024[10]. - The net deferred tax asset as of December 31, 2025, was $464,000, a decrease from $501,000 in 2024, primarily due to changes in R&D expenses and valuation allowances[13]. Corporate Governance - Management's assessment confirmed that internal controls over financial reporting were effective as of December 31, 2025, ensuring compliance with SEC regulations[20]. - The Audit Committee is comprised of independent directors, ensuring oversight and compliance with financial reporting standards[22]. - The Company has adopted a Code of Ethics and Business Conduct applicable to all employees, reinforcing its commitment to ethical practices[21]. Compensation and Incentives - The total compensation for David L. Klenk, President and CEO, in 2025 was $354,468, an increase from $316,916 in 2024, driven by a higher bonus[16]. - The 2025 Plan allocated 40% of the potential bonus to financial performance, 50% to strategic initiatives, and 10% was discretionary, with an incentive cash payment of approximately 18% of Mr. Klenk's base salary[221] - The 2026 Management Incentive Plan allocates 50% of the potential bonus to financial performance, 40% to strategic initiatives, and 10% is discretionary, with an incentive cash payment of approximately 21% of Mr. Klenk's base salary if goals are achieved[222] Audit and Compliance - The Company paid $124,370 in audit fees to Boulay PLLP for 2025, an increase from $107,000 in 2024[240] - Total fees paid to Boulay PLLP in 2025 amounted to $133,370, compared to $121,135 in 2024[240] - The independent auditor will provide statutory and financial audits, as well as audit services related to SEC registration statements and periodic reports[47]

Financial Performance - The company reported a significant increase in revenue, achieving $1.5 billion for the year ended December 31, 2025, representing a 15% growth compared to the previous year[8]. - The company reported a net income of $400 million, reflecting a 12% increase year-over-year, driven by operational efficiencies and cost management[8]. - Gold Fields reported a significant increase in production, achieving a total output of 2.5 million ounces of gold, representing a 10% increase year-over-year[90]. - Gold Fields reported a strong performance with a revenue increase of 15% year-over-year, reaching $1.2 billion in Q3 2023[178]. - The company reported a 20% increase in cash flow from operations, totaling $500 million, driven by higher gold prices and operational efficiencies[90]. Future Projections and Guidance - The company provided guidance for 2026, projecting revenue growth of 10-12% based on anticipated market conditions and product demand[9]. - The company anticipates a production guidance of 2.6 million ounces for the next fiscal year, reflecting a growth of 4%[90]. - The company plans to increase production by 10% in 2026, driven by operational improvements and new technology implementations[119]. - The company provided an optimistic outlook for Q4 2023, projecting revenue growth of 10% to 12%[178]. Market Expansion and Strategic Initiatives - The company plans to expand its market presence in Asia, targeting a 25% increase in market share within the next two years[9]. - New product launches are expected to contribute an additional $200 million in revenue, with a focus on innovative technologies in the mining sector[9]. - The company is focusing on expanding its operations in Peru, with an investment of $300 million planned for the next three years to enhance mining capabilities[90]. - Market expansion efforts include entering three new international markets, projected to increase market share by 5%[178]. Sustainability and Environmental Initiatives - Environmental initiatives are being prioritized, with a commitment to reduce carbon emissions by 30% by 2026[9]. - The company has set ambitious sustainability targets, aiming for a 30% reduction in greenhouse gas emissions by 2026[90]. - The company is committed to reducing its carbon footprint by 30% by 2030, aligning with global sustainability goals[111]. - A new sustainability initiative is set to reduce operational costs by 8% over the next two years[178]. Governance and Ethical Practices - The board emphasized the importance of ethical governance and stakeholder engagement in its annual report, highlighting a commitment to responsible mining practices[7]. - The company is committed to ethical business practices, with robust mechanisms in place to ensure regulatory compliance and good governance principles[163]. - The Board is focused on fair remuneration practices aligned with strategy and promoting business performance, ensuring transparency in executive remuneration[176]. - The company is committed to ethical business practices and good governance as part of its strategic initiatives[180]. Operational Efficiency and Cost Management - Capital expenditures for 2026 are projected at $300 million, aimed at enhancing operational efficiency and expanding production capacity[8]. - The company is focused on enhancing operational efficiencies and asset optimization to manage cost pressures while maintaining strong production levels[135]. - The company is enhancing stakeholder engagement through a new Business Partner Framework aimed at improving collaborative relationships[156]. Acquisitions and Investments - The company is exploring strategic acquisitions to bolster its portfolio, with a budget of $500 million allocated for potential mergers and acquisitions[9]. - Gold Fields is actively pursuing strategic acquisitions to enhance its mineral resource base, with a target of increasing reserves by 15% over the next five years[90]. - The company is considering strategic acquisitions to bolster its technology portfolio, with a budget of $100 million allocated for potential deals[178]. - Gold Fields completed the acquisition of Gold Road Resources, consolidating 100% ownership of the Gruyere asset, which is expected to enhance the quality of its portfolio[139]. Safety and Community Impact - The total recordable injury frequency rate (TRIFR) improved to 2.5 per million hours worked, indicating a 15% reduction in workplace injuries[86]. - The company reported no work-related fatalities in 2025, marking a significant milestone in its safety performance[133]. - Gold Fields' socio-economic development spend reached $20 million, enhancing community relations and local development initiatives[105]. Board and Leadership Structure - The Board currently comprises 13 directors, including 2 executive directors and 11 independent non-executive directors (NEDs)[181]. - The Board has maintained a majority of independent NEDs since the Company's inception, ensuring independent judgment in discussions and decisions[182]. - The Board's diversity targets include 30% female representation across the workforce by 2030[184]. - The Board's governance structure emphasizes adherence to sound corporate governance standards and effective oversight of business operations[192].

Financial Performance - Fourth quarter net income improved to $0.9 million compared to a net loss of $0.3 million in the prior year period[1] - Revenue for the fourth quarter was $1.50 million, a decrease of approximately 11.0% from $1.68 million in the prior year, primarily due to a shift in the Amazon business model[5] - Gross profit for the fourth quarter was $0.67 million, with a gross margin of 44.9%, down 1400 basis points year-over-year[5] - Full-year revenue increased to $6.61 million, reflecting a 0.7% increase from $6.57 million in the prior year[5] - The company reported a gross profit of $3.48 million for the full year, with a gross margin of 52.7%, down 220 basis points year-over-year[5] - Net income for the year ended December 31, 2025, was $758,478, compared to a net loss of $559,356 in 2024[16] Assets and Liabilities - Total assets increased to $9.11 million as of December 31, 2025, compared to $7.17 million in the prior year[12] - Total liabilities rose to $7.57 million from $7.29 million in the previous year[12] - Stockholders' equity improved to $1.54 million from a deficit of $0.12 million in the prior year[12] Cash Flow and Financing - Cash flows from operating activities resulted in a net cash used of $1,271,544, a significant decrease from a net cash provided of $1,990 in the previous year[16] - Total cash at the end of the period increased to $2,726,696 from $211,642 at the beginning of the period[16] - The company recorded a significant financing activity with proceeds from the issuance of preferred stock amounting to $8,000,000[16] - The company incurred a deferred offering cost of $1,721,228, compared to $163,125 in the previous year[16] - Stock-based compensation increased to $543,068 from $414,900 year-over-year[16] - The company reported a loss on the issuance of preferred stock of derivative liabilities totaling $5,294,242[16] - Cash paid for interest increased to $401,411 from $224,428 in the previous year[16] - The company recognized a derivative liability of preferred stock amounting to $13,294,242[17] - Common stock was issued for convertible note payable and accrued interest totaling $122,331[17] Product Development - The company launched Tru2u.health, a digital health platform, in February, integrating various health solutions into a seamless consumer experience[6] - The Kirkman brand portfolio was expanded with two new product bundles, enhancing market offerings[6]

Financial Position and Debt - As of December 31, 2025, OPC had outstanding indebtedness of $1,769 million, with an additional $1,376 million in debt from CPV's associated companies[88]. - Kenon's stake in OPC decreased from approximately 55% at the beginning of 2025 to approximately 46% due to participation in only one of four equity capital raises conducted by OPC[63]. - OPC and its subsidiaries require additional financing for ongoing construction and development projects, which may impact their operational strategies[62]. - The company relies on cash flows from its businesses to meet obligations, and any limitations on distributions could affect its financial flexibility[83]. - High levels of leverage increase sensitivity to market conditions, with significant portions of cash flows used for debt service, limiting operational funding[89]. - The ability to execute future investments or acquisitions may depend on obtaining necessary regulatory approvals and favorable financing conditions[74]. - As of December 31, 2025, OPC had $1,769 million in consolidated indebtedness, which may affect its ability to comply with financial covenants[133]. - High leverage levels pose risks to OPC's ability to secure funding for future strategic plans, potentially impacting credit ratings and operational results[159]. - OPC's dependency on dividends from subsidiaries may limit cash flow availability, affecting its ability to meet liabilities[161]. Market and Economic Risks - Disruptions in financial markets could adversely affect the ability of OPC and Kenon to access capital on acceptable terms, impacting liquidity and investment strategies[77]. - Global economic conditions, including geopolitical events and commodity price fluctuations, could adversely affect the company's business and operating results[108]. - The ongoing military conflicts and their impact on supply chains may lead to project delays and operational disruptions[112]. - Global geopolitical instability, including conflicts and economic uncertainty, may disrupt OPC's supply chain and financing availability[162]. - The political and security situation in Israel could adversely impact OPC's operations and financial stability, affecting project execution and compliance with financing agreements[166]. Operational and Regulatory Challenges - The company faces risks related to potential acquisitions or investments, including the challenge of identifying suitable opportunities and the potential for unfavorable terms[70]. - OPC's operations are significantly influenced by government regulations, with recent changes in the tariff structure in Israel impacting its results[139]. - The company may face limitations in raising debt financing due to regulatory restrictions imposed on financial institutions regarding loans to single borrowers[136]. - OPC's ability to expand its business may be limited by existing regulations, including competition laws and the Electricity Sector Law in Israel[149]. - OPC's operations are subject to increasing scrutiny regarding environmental, social, and governance (ESG) goals, which may affect its financing and operational costs[137]. - Legal and compliance risks are prevalent, with potential enforcement actions and penalties that could disrupt operations and increase costs[122]. - Changes in international sanctions and trade restrictions could expose OPC to civil or criminal penalties, adversely affecting financial condition and operations[128]. Supply Chain and Resource Risks - The company faces risks related to raw material shortages and supplier capacity constraints, which could increase operating costs[114]. - OPC faces risks related to supply chain disruptions, including reliance on limited suppliers for raw materials, which could increase operating costs and affect product quality[116]. - Fuel supply disruptions and price fluctuations, particularly for natural gas, may adversely impact OPC's operating results[211][213]. - OPC relies on key suppliers for construction and maintenance, and any failure to meet performance targets may lead to project delays and financial losses[216]. - The ability to secure grid connections and infrastructure is critical for OPC's operations, with potential adverse effects from disruptions or insufficient capacity[217][219]. Cybersecurity and Technological Risks - Cybersecurity threats are increasing, with potential attacks leading to business disruptions and significant costs for system recovery and protection measures[121]. - OPC employs a multi-faceted approach to protect its generation facilities against cyber-attacks, with heightened risks due to the current geopolitical situation[176]. - The use of AI platforms is increasing, but it remains in a developmental phase, exposing OPC to potential cybersecurity risks and operational disruptions[193]. - Compliance with cybersecurity standards is critical, as cyber-attacks could lead to operational delays and increased costs for CPV[241]. Project Development and Execution Risks - The company is working to expand its renewable energy activities in Israel and the United States, potentially incorporating carbon capture technologies[132]. - OPC is pursuing the development and construction of several significant projects concurrently, increasing exposure to development and construction risks[205]. - The construction of the Sorek 2 project faced disruptions due to force majeure notices from contractors and the evacuation of teams, impacting the project's timeline[182]. - Delays in project completion may result in increased costs and forfeiture of collateral or pre-operation investments[252]. - CPV's projects depend on third-party suppliers, and disruptions in supply chains could adversely affect operations and costs[243]. Labor and Human Resource Risks - The company requires qualified personnel to manage operations, and challenges in hiring and retention could adversely affect business performance[113]. - OPC faces challenges in recruiting and retaining skilled employees, which could impact project execution and operational efficiency[187]. Environmental and Compliance Risks - OPC's operations are subject to health and safety risks, including potential civil or criminal procedures due to safety incidents, which may lead to reputational damage[197]. - Legislative changes and stricter environmental standards may increase costs and expose OPC to penalties, sanctions, and remediation expenses[199]. - Environmental regulations may impose significant costs on CPV, requiring investments to comply with stricter standards[245]. - The construction and operation of renewable energy projects face environmental risks, including potential penalties for harming endangered species[251].

Investment and Product Development - The company has invested significant resources in developing products compatible with Microsoft Teams, Zoom, and Cisco Webex, which are critical for maintaining partnerships and market presence[43] - The company is investing in AI and machine learning technologies, including the development of software-based voice productivity solutions under the VoiceAI business line[82] - AudioCodes has expanded its operations to include voice communications solutions for enterprises, contact centers, and service providers, focusing on multiple markets such as VoIP and unified communications[200] - The company has developed a cloud-based service delivery platform, Live Platform, which supports voice connectivity and AI-based communication services, enhancing its offerings across North America, Europe, and Asia Pacific[209] - AudioCodes expanded its portfolio of voice AI services in 2025, introducing Meeting Insights and real-time analytics capabilities, aimed at enhancing service provider offerings and customer experience[212] Geopolitical and Economic Risks - The ongoing geopolitical tensions and military conflicts in Israel have not significantly impacted the company's supply chains or operations to date, although there are risks associated with potential future escalations[37] - Recent military conflicts have led to a review and downgrade of Israel's credit rating by agencies such as Fitch and S&P Global, which could disrupt the business environment and capital raising efforts[39] - The company faces risks from adverse macroeconomic conditions, including inflation and potential recessionary pressures, which could affect its business performance[32] - Political and military conditions in Israel directly affect the company's operations, with recent escalations in conflict since October 2023 impacting business stability[113] - The conflict in Ukraine may result in significant regional instability and adverse effects on global macroeconomic conditions, impacting the company's financial condition[109] Supply Chain and Operational Challenges - There are significant global shortages of critical components necessary for manufacturing, which could hinder the company's ability to meet market demand[35] - Supply chain risks exist due to reliance on a limited number of suppliers for key components, which could disrupt product delivery and increase costs[70][71][72] - The company relies on a small number of sole source suppliers for components, which poses a risk of supply interruptions and potential redesigns of products if alternative sources are not found[73] - The company is heavily reliant on third-party intermediaries for product sales, which limits control over end-user selections and may impact revenue[32] - The company relies on third-party distributors and OEMs for sales, which limits direct access to end-user requirements and may affect product demand[53] Financial Performance and Revenue Risks - The company anticipates fluctuations in quarterly results, which may require revised guidance and could adversely affect share price if expectations are not met[32] - A limited order backlog means that revenue levels are highly dependent on orders received and delivered within the same quarter, which could adversely affect results of operations if expectations are not met[96] - The sales cycles for the company's products typically range from six to twelve months, which complicates revenue predictability and increases costs associated with obtaining orders[76] - Gross margin could be negatively impacted by amortization expenses from acquisitions and increased manufacturing costs, which may adversely affect results of operations[97] - Uncertain economic conditions may lead to reduced consumer spending, adversely impacting sales and potentially increasing credit risk related to customer receivables[98] Compliance and Regulatory Challenges - The company faces risks related to obtaining product certifications from national regulators, which can be time-consuming and may affect market access[80] - The company is subject to various regulations that may increase costs and affect operations, particularly regarding environmentally friendly materials and waste management[137] - Compliance with the General Data Protection Regulation (GDPR) can result in fines of up to EUR 20 million or 4% of total worldwide annual turnover, whichever is higher[144] - The California Consumer Privacy Act (CCPA) requires businesses to provide disclosures regarding personal information collection and to respond to access and deletion requests from California residents[147] - The company may incur significant costs related to compliance with evolving data privacy laws and regulations, which could impact financial performance[149] Competition and Market Dynamics - Intense competition in the industry, including mergers and acquisitions, may hinder the company's ability to maintain profitability[54] - The company competes with major players in various segments, including Oracle, Cisco, and Twilio, across multiple product lines[55][56][57][58][59][60][61][62] - The ongoing shift to IP networks is leading to a decline in demand for media gateway products, adversely affecting revenue from this segment[49] - The transition to cloud-based software poses challenges, as the company primarily generates revenue from on-premises deployments, which may not align with market trends[50] - OEM customers may opt to develop their own solutions or use third-party technologies, potentially reducing demand for the company's products[52] Cybersecurity and Technology Risks - The company is exposed to cybersecurity risks that could damage its brand and result in financial penalties[35] - The company faces significant cybersecurity risks that could adversely affect its operations and financial results, including potential data breaches and legal liabilities[183] - The company is increasingly incorporating open source software into its products, which may introduce vulnerabilities to cyberattacks[185] - The introduction of AI technologies may expose the company to new legal, regulatory, and operational risks, potentially harming financial results[151] - The regulatory landscape for AI in the U.S. is uncertain, with various states enacting their own laws, creating a complex compliance environment[153] Human Resources and Labor Costs - The company has experienced increased wage-related expenses in Israel due to a shortage of skilled R&D employees, impacting recruitment and operational costs[35] - Rising wages and labor-related costs in Israel are expected to impact the company's financial condition and operations due to competition for qualified talent[182] - The company relies heavily on key personnel, including the President and CEO, and any loss of these individuals could materially affect operations[180] Strategic Growth and Future Outlook - The company is committed to expanding its international operations, which presents both growth opportunities and associated risks[35] - The company plans to expand its international operations, which may increase revenues but also exposes it to risks such as contract enforcement difficulties and increased operational costs[178] - The company may pursue acquisitions to expand its business, but such activities could divert resources and disrupt operations, potentially affecting results[191] - The company may require additional financing to support operations and long-term expansion plans, with uncertainty regarding the ability to raise funds on favorable terms[95]

Financial Performance - Reported revenue for full year 2025 totaled $791.0 million, a decline of 9.4% year-over-year[6] - Combined pro forma revenue for full year 2025 was $879.6 million, a decline of 13.6% year-over-year[6] - GAAP net income for 2025 was $1.1 billion, compared to a net loss of $215.2 million in the prior year[6] - Pro forma normalized EBITDA for full year 2025 was $90.2 million, a decrease of 13.7% year-over-year[6] - Fourth quarter revenue totaled $207.0 million, a decline of 15.1% year-over-year on a pro forma basis[6] - Reported revenue for FY 2025 was $791,042, a decrease of 9.3% from FY 2024's $872,690[39] - Pro forma revenue for FY 2025 adjusted to $879,600, down 13.6% from FY 2024's $1,017,618[39] - Reported gross profit for FY 2025 was $171,670, a decline of 9.1% compared to FY 2024's $188,766[39] - Pro forma normalized EBITDA for FY 2025 was $90,167, down 13.6% from FY 2024's $104,442[41] Contract Value and Growth Initiatives - Closed total contract value (TCV) of $297.8 million, including $163.8 million of new TCV[6] - New TCV closed in the fourth quarter was $60.2 million, a 53.2% increase year-over-year[6] - The company has strategically invested in sales leadership and AI initiatives to drive growth and operational efficiency[5] - XBP Global aims to stabilize its portfolio and return to growth following the acquisition of Exela Technologies BPA[4] Assets and Liabilities - Total assets increased to $902.097 million as of December 31, 2025, up from $390.421 million in the previous year[31] - Current liabilities totaled $322.043 million, significantly reduced from $1.790206 billion in the previous period[31] - The total stockholder's equity was $87.339 million, a significant improvement from a deficit of $1.456788 billion in the previous year[31] Cash Flow and Expenses - Net cash provided by operating activities for the period was $18,232, compared to a net cash used of $(159,942) in the previous period[37] - Net cash used in investing activities was $(6,336), an increase from $(2,690) in the prior period[37] - Net cash provided by financing activities was $13,109, a significant decrease from $145,264 in the previous period[37] - Selling, general and administrative expenses were $49.669 million, slightly down from $53.946 million in the previous period[34] - Interest expense for the period was $24.237 million, a decrease from $75.226 million in the previous period[34] Impairment and Deficits - The impairment of goodwill was recorded at $320.292 million, indicating a significant write-down[34] - The company reported a net loss of $351.123 million for the same period, compared to a net profit of $1.454658 billion in the previous period[34] - The company’s accumulated deficit reached $351.123 million as of December 31, 2025[31]

Revenue Performance - Reported revenue for full year 2025 totaled $791.0 million, a decline of 9.4% year-over-year[6] - Combined pro forma revenue for full year 2025 was $879.6 million, a decline of 13.6% year-over-year[6] - Fourth quarter revenue totaled $207.0 million, a decline of 15.1% year-over-year on a pro forma basis[6] - The applied workflow automation segment reported revenue of $723.2 million for FY 2025, down 11.4% from FY 2024[7] - The technology segment reported revenue of $67.8 million for FY 2025, an increase of 20.6% from FY 2024[7] - Reported revenue for FY 2025 was $791,042,000, a decrease of 9.3% from $872,690,000 in FY 2024[39] - Pro forma revenue for FY 2025 adjusted to $879,600,000, down 13.6% from $1,017,618,000 in FY 2024[39] Profitability Metrics - GAAP net income for 2025 was $1.1 billion, compared to a net loss of $215.2 million in the prior year[6] - Pro forma normalized EBITDA for 2025 was $90.2 million, a decrease of 13.7% year-over-year[6] - Reported gross profit for FY 2025 was $171,670,000, a decline of 9.1% compared to $188,766,000 in FY 2024[39] - Pro forma gross profit for FY 2025 was $192,335,000, down 12.7% from $220,298,000 in FY 2024[39] - Pro forma net income for FY 2025 was $1,090,175,000, a significant recovery from a loss of $227,294,000 in FY 2024[41] - Net loss for the three months ended December 31, 2025, was $45,286,000, compared to a loss of $134,987,000 for the same period in 2024[41] Cash Flow and Expenses - Cash provided by operating activities for the period was $18,232,000, a recovery from cash used of $159,942,000 in the previous period[37] - Net cash used in investing activities was $6,336,000, compared to $2,690,000 in FY 2024[37] - Net cash provided by financing activities was $13,109,000, a decrease from $145,264,000 in FY 2024[37] - Selling, general and administrative expenses were $49.669 million, slightly down from $53.946 million[34] - The company incurred interest expenses of $24.237 million, down from $75.226 million in the previous period[34] Balance Sheet Highlights - Total assets increased to $902.097 million as of December 31, 2025, up from $390.421 million in the previous year[31] - Current liabilities totaled $322.043 million, significantly reduced from $1.790206 billion in the previous period[31] - The company’s total liabilities decreased to $814.758 million from $1.847209 billion[31] - The impairment of goodwill was recorded at $320.292 million, indicating a significant write-down[34] - Cash and cash equivalents rose to $37.113 million, compared to $11.635 million in the previous period[31] Strategic Focus - The company is focused on stabilizing its portfolio and laying the groundwork for a return to growth through strategic investments in sales leadership and AI initiatives[5] - Closed total contract value (TCV) of $297.8 million, including $163.8 million of new TCV[6]

Clinical Trials and Enrollment - Enrollment completed in two pivotal trials of VDPHL01 for male patients, with topline data expected from Study 302 in 1H 2026 and Study 304 in 2H 2026[1] - Over 1,000 male participants enrolled in Studies 302 and 304, representing one of the largest registration-directed programs for pattern hair loss (PHL) to date[4] - Enrollment ongoing in Study 306, the first Phase 2/3 trial of an oral treatment for female pattern hair loss, expected to enroll over 500 female patients[4] Financial Performance - Cash, cash equivalents, and marketable securities totaled $141.9 million as of December 31, 2025, with an upsized IPO raising approximately $294.8 million completed in February 2026[6][7] - Net loss for the fourth quarter of 2025 was $21.8 million, compared to a net loss of $5.7 million for the same period in 2024[11] - Net loss for the year ended December 31, 2025, was $69,995,000, up from a net loss of $26,488,000 in 2024, reflecting a 164% increase[18] - Total other income, net, for the year ended December 31, 2025, was $2,352,000, compared to $290,000 in 2024, reflecting a significant increase[18] Expenses - Research and development (R&D) expenses increased to $62.1 million for the year ended December 31, 2025, compared to $23.3 million for the previous year[11] - General and administrative (G&A) expenses rose to $10.3 million for the year ended December 31, 2025, compared to $3.5 million for the previous year[11] - Research and development expenses increased to $18,192,000 in Q4 2025 from $4,950,000 in Q4 2024, representing a 267% increase[18] - Total operating expenses rose to $23,011,000 in Q4 2025 compared to $5,971,000 in Q4 2024, marking a 285% increase[18] - Loss from operations for the year ended December 31, 2025, was $72,347,000, compared to $26,778,000 in 2024, a 170% increase[18] Assets and Liabilities - Cash, cash equivalents, and marketable securities increased significantly to $141,862,000 in 2025 from $53,084,000 in 2024, a growth of 167%[20] - Total assets grew to $152,619,000 in 2025, up from $55,535,000 in 2024, indicating a 174% increase[20] - Total liabilities increased to $9,156,000 in 2025 from $4,718,000 in 2024, a rise of 94%[20] - Total stockholders' equity and redeemable convertible preferred stock reached $143,463,000 in 2025, compared to $50,817,000 in 2024, representing a 182% increase[20] Leadership Changes - Mark Neumann appointed as Chief Commercial and Strategy Officer, bringing over 30 years of biopharmaceutical experience[7] Product Development - VDPHL01 is an investigational, orally available non-hormonal drug in Phase 3 development for PHL, with a proprietary extended-release formulation designed to improve efficacy and safety[9] - Anticipated milestones for 2026 include two Phase 3 readouts for men and progress towards a planned NDA submission for VDPHL01[2]

Acquisition and Strategic Partnerships - The company completed the acquisition of dual-targeting CAR-T programs, issuing 8,268,495 shares of common stock as part of the transaction[18]. - The strategic acquisition includes rights to TPST-2003, TPST-2206, TPST-3003, and TPST-3206, enhancing the company's oncology pipeline[19]. - The company entered into a license agreement with Novatim, with potential milestone payments totaling up to $1.32 billion[112]. - The company entered into a collaboration agreement with Roche in February 2021 to accelerate the development of amezalpat, which is currently being evaluated in a Phase 1b/2 clinical study[121]. Clinical Development and Trials - Amezalpat (TPST-1120) is Phase 3-ready for first-line hepatocellular carcinoma (HCC), with positive Phase 2 data showing a six-month improvement in median overall survival[30]. - The company plans to initiate a Phase 2 study for TPST-1495 in familial adenomatous polyposis (FAP) in 2026, funded by the National Cancer Institute[34]. - TPST-2003, the lead CAR-T therapy, is currently in a Phase 1/2a clinical trial for relapsed or refractory multiple myeloma (rrMM) and aims to initiate a registrational Phase 2b trial in China by the end of 2026[36]. - The planned Phase 3 trial for amezalpat will compare its efficacy with standard care, with a primary endpoint of overall survival[31]. - TPST-3003, an allogeneic dual-targeting CAR-T product, is planned for evaluation in patients with relapsed/refractory multiple myeloma (rrMM) with enrollment potentially beginning in Q3 2026[67]. - TPST-4003, an in vivo dual-targeting CAR-T product, is being developed for lupus, with enrollment in a strategic partner-sponsored trial potentially starting in Q2 2026[70]. - TPST-2206, an autologous dual-targeting CAR-T product for renal cell carcinoma (RCC), is planned for a Phase 1 clinical trial starting in Q2 2026[72]. - The Phase 1 trial of TPST-1495 showed tumor shrinkage and prolonged stable disease in a treatment-refractory patient population, with a tolerable safety profile[108]. Product Efficacy and Outcomes - TPST-2003 demonstrated a complete response (CR) rate of 100% (6/6) among evaluable patients in the REDEEM-1 trial as of January 31, 2026[57]. - Overall response rate (ORR) was 100% (25/25) among 25 evaluable patients with measurable disease at baseline across both studies[58]. - Amezalpat demonstrated a 53% clinical benefit rate in late-line, treatment-refractory cancers, with 21% of patients experiencing tumor shrinkage[82]. - In the ongoing global randomized Phase 1b/2 trial for advanced HCC, the median overall survival (OS) in the amezalpat arm reached 21 months, a 6-month improvement over the 15-month OS in the control arm[90]. - The confirmed overall response rate (ORR) for the amezalpat arm was 30%, compared to 13.3% in the control arm, with a notable 43% ORR in patients with β-catenin mutations[92][93]. - In the combination therapy portion of the trial, 50% of evaluable RCC patients achieved an objective response rate (ORR) of 50%[84]. - A patient in the amezalpat arm converted from a partial response (PR) to a complete response (CR) with at least an 80% reduction in tumor burden[92]. Regulatory Designations and Compliance - The company received Orphan Drug Designation and Fast Track Designation from the FDA for amezalpat, which may provide regulatory benefits[32]. - The company plans to submit an Investigational New Drug (IND) application to the FDA and may initiate a U.S. registrational study in 2026 based on current data[64]. - The FDA requires extensive data demonstrating quality, safety, and efficacy before a new pharmaceutical product can be marketed[149]. - The FDA review process for NDAs typically takes about 10 months for standard reviews and 6 months for priority reviews[164]. - Orphan drug designation can provide a seven-year exclusive marketing period in the U.S. for products that receive the first FDA approval for a rare disease, with additional benefits such as tax credits for research[173]. - Fast track designation allows for expedited review of products intended to treat serious conditions, with the FDA required to determine qualification within 60 days of request[175]. - Breakthrough therapy designation may be granted for products showing substantial improvement over existing therapies, allowing for increased interaction with the FDA during development[176]. - The company must comply with Good Manufacturing Practices (cGMP) to ensure consistent production of its products[167]. Intellectual Property and Patent Strategy - The company has filed patents for amezalpat, expected to expire between December 2033 and November 2043, and for TPST-1495, expected to expire between April 2038 and April 2039[100][110]. - As of February 28, 2026, the company holds one pending U.S. patent application and nine pending patent applications for TPST-2003, with expected patent expiration in March 2044[136]. - The patent portfolio for amezalpat includes ten issued U.S. patents and 68 issued patents in various markets outside the U.S., with expected expiration in December 2033[140][141]. - The company intends to pursue patent protection for its product candidates, including compositions, methods of use, and manufacturing processes[144]. - The patent positions of the company are uncertain, with no consistent policy regarding the scope of claims allowable in oncology patents in the U.S.[147]. - The company faces risks that third parties may have blocking patents, which could hinder commercialization of its product candidates[148]. Market and Competitive Landscape - The company is aware of intense competition in the biopharmaceutical industry, particularly for cancer treatments, with competitors including Merck, Roche, and AstraZeneca[128][130]. - The company faces potential limitations in commercial opportunities if competitors develop more effective or safer products[134]. - Coverage and reimbursement decisions for pharmaceutical products are critical and can vary significantly among third-party payors, impacting product acceptance[191]. - Third-party payors increasingly require discounts and challenge pricing, which can delay coverage and reimbursement for newly approved drugs[193]. - The commercialization of therapeutics outside the U.S. is subject to extensive governmental price controls, impacting pricing and usage[194]. Company Operations and Workforce - As of March 1, 2026, the company had four employees, all full-time, with three holding advanced degrees[210]. - The company aims to attract and retain talent by offering competitive salaries, bonuses, and equity ownership opportunities[211]. - The company emphasizes diversity and inclusion in its workforce, encouraging applications from underrepresented groups in the biotech industry[212]. - The company is committed to maintaining compliance with healthcare laws and regulations, which involves substantial costs and risks[204]. - The current administration's policies may lead to reduced drug prices and increased operational costs for manufacturers[208]. - The company is focused on developing internal expertise in cellular biology and clinical development to enhance its product pipeline[210]. - The company has established a code of business conduct and ethics to ensure appropriate behavior among employees[212]. - The company’s headquarters is located in Brisbane, California, and it was incorporated in Delaware in April 2011[213].